Filing summary: Pieris Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Issuer identification: The filing is for Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), not Palvella Therapeutics, Inc., the company named in the request metadata. Period ended June 30, 2021; financial statements are unaudited. Dollar amounts below are in millions unless noted.
Business context and reporting period
Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based medicines. It has no product sales; revenue comes from collaboration and licensing agreements. Key programs include partnered respiratory candidate PRS-060/AZD1402, proprietary PRS-220, and immuno-oncology candidate cinrebafusp alfa.
Financial results and liquidity
| Metric | Three months ended June 30, 2021 | Six months ended June 30, 2021 |
|---|---|---|
| Total revenue | $3.3 | $18.9 |
| Research and development expense | $15.8 | $32.4 |
| General and administrative expense | $4.2 | $8.4 |
| Net loss | $(15.5) | $(19.7) |
| Net loss per share, basic and diluted | $(0.25) | $(0.33) |
- Cash and cash equivalents were $119.1 at June 30, compared with $70.4 at December 31, 2020. Current assets were $127.7 and current liabilities $43.9, implying working capital of approximately $83.7.
- Six-month operating cash flow was positive $17.8, versus negative $24.9 in the prior-year period. The company attributed the current-period cash generation chiefly to higher deferred revenue and accrued liabilities, so it should not be read as operating profitability.
- Investing cash flow was negative $0.3; financing cash flow was positive $32.3. Financing included $12.2 net proceeds from ATM sales and $18.9 from private placements, plus proceeds from warrant and option exercises.
- Total liabilities were $108.3, including deferred revenue of $74.9. Operating lease liabilities were approximately $15.9; the filing reports no material debt borrowings. No gross margin is reported, and product-sales margins are not applicable because Pieris has no product revenue.
- Accumulated deficit was $231.1. Common shares outstanding increased from 56.0 million at year-end 2020 to 66.7 million at June 30, 2021.
Material changes versus the prior comparable period
- Q2 revenue fell to $3.3 from $11.2, and six-month revenue fell to $18.9 from $24.5. The prior-year comparisons included Seagen milestone and amendment-related revenue and Servier revenue from programs later discontinued. Six-month 2021 revenue included a $13.0 AstraZeneca milestone recognized in Q1 after initiation of the PRS-060/AZD1402 Phase 2a study.
- Q2 net loss widened to $15.5 from $5.0; the six-month loss widened to $19.7 from $8.5. R&D expense increased 34% for the half-year, mainly from higher PRS-220 respiratory work and immuno-oncology manufacturing costs, including cinrebafusp alfa.
- In May, Genentech entered a research collaboration and paid a $20.0 upfront fee. Pieris also licensed PRS-342 to Boston Pharmaceuticals for a $10.0 upfront payment, subject to up to $4.0 of manufacturing-cost funding by Pieris. These agreements increased deferred revenue; the BP agreement’s initial accounting transaction price was $6.0 after the expected manufacturing reimbursement.
- Cash increased in part through equity financing, including strategic investments by Seagen and AstraZeneca and ATM sales. ATM sales during Q2 totaled approximately 3.0 million shares at an average price of $4.24.
Outlook, management commentary, and risks
- Management said available funds were expected to support operations for at least 12 months from the August 5, 2021 filing date. It expects substantial operating losses and rising development costs for several years, and plans to pursue equity financing, ATM sales, collaborations, licensing, milestones, and grants. Future financing is not assured and could dilute existing shareholders.
- PRS-060/AZD1402 Phase 2a enrollment was underway, with AstraZeneca sponsoring and funding the study. Pieris expected to report results from both planned cinrebafusp alfa Phase 2 gastric-cancer arms the following year; the filing described a HER2-high arm with ramucirumab and a HER2-low arm with tucatinib. Cinrebafusp alfa received FDA orphan-drug designation in June.
- PRS-220 was in IND-enabling work, with clinical development expected to begin in 2022. Pieris was selected for a Bavarian grant of €14.2 million (about $17.0 million) for qualifying PRS-220 research and development; $0.8 million of grant income was recognized in the first half. Grant funding is conditional and tied to eligible costs.
- Key risks include clinical and regulatory failure or delay, substantial ongoing funding needs, reliance on collaboration partners and third-party manufacturers, intellectual-property risks, and possible effects of COVID-19 on research, supply chains, and trials. The filing reported no material changes to the risk factors in the 2020 Form 10-K and no material pending legal proceedings.
- Management concluded disclosure controls were effective as of June 30, 2021; no material change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Confirm the issuer: this is Pieris Pharmaceuticals’ filing, not a Palvella Therapeutics filing.
- Track cash use and whether the $119.1 million balance supports the stated runway as trial and manufacturing costs rise; operating cash flow benefited from deferred revenue and working-capital movements.
- Monitor clinical execution and results for cinrebafusp alfa and PRS-060/AZD1402, and progress toward PRS-220’s planned clinical start.
- Assess the timing, conditions, and durability of collaboration revenue, milestone payments, and Bavarian grant reimbursements; potential milestone totals are contingent, not assured.
- Review further equity issuance and dilution, collaboration termination provisions, and the cost of Pieris’s long-term facility lease.